Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to “Hold” at StockNews.com

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report released on Wednesday.

Several other research analysts also recently commented on the stock. Scotiabank initiated coverage on shares of Agios Pharmaceuticals in a report on Wednesday. They set a “sector outperform” rating and a $51.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Finally, Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $52.00.

Agios Pharmaceuticals Stock Up 3.9 %

AGIO stock traded up $1.66 during trading on Wednesday, reaching $43.70. The company’s stock had a trading volume of 495,570 shares, compared to its average volume of 704,252. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $53.28. The company has a market capitalization of $2.48 billion, a P/E ratio of -6.91 and a beta of 0.75. The company’s fifty day moving average is $44.58 and its 200-day moving average is $40.85.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. During the same quarter in the previous year, the company posted ($1.51) EPS. The company’s quarterly revenue was up 28.4% on a year-over-year basis. Analysts anticipate that Agios Pharmaceuticals will post -4.87 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 34.1% during the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock worth $163,469,000 after acquiring an additional 1,423,000 shares during the period. Marshall Wace LLP increased its position in shares of Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after acquiring an additional 855,739 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after acquiring an additional 388,381 shares during the period. Frazier Life Sciences Management L.P. increased its position in shares of Agios Pharmaceuticals by 66.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after acquiring an additional 348,808 shares during the period. Finally, Candriam S.C.A. purchased a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $13,922,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.